GE HealthCare recently announced CareIntellect for Oncology, a pioneering cloud-based application that integrates multi-modal patient data into a unified view to support oncologists with advanced insights. Leveraging generative AI, the application summarizes clinical notes and complex medical histories to give care teams a clear perspective on a patient's health journey and disease progression. Initially targeting prostate and breast cancer, CareIntellect for Oncology synthesizes structured and unstructured data, including medical images, records, and device readings, to assist in clinical trial eligibility assessments, treatment response evaluations, and protocol adherence monitoring. This innovation is set to launch in the U.S. by 2025, with Tampa General Hospital and UT Southwestern Medical Center serving as early evaluators.
CareIntellect is part of GE HealthCare’s larger family of applications designed to streamline the integration of advanced tools into healthcare settings, reducing the burdensome and time-intensive task of multiple product installations. The application minimizes the time clinicians spend navigating disparate systems, giving them more time for patient care. With 51,000 employees globally and $19.6 billion in revenue, GE HealthCare remains a leader in digital health solutions. By addressing both clinical and operational needs, CareIntellect represents GE HealthCare’s commitment to advancing personalized, efficient, and connected healthcare for patients and providers worldwide.
